Serum level of follicle-stimulating hormone is associated with extraprostatic extension of prostate cancer  by Ide, Hisamitsu et al.
109
Copyright © 2013 Asian Pacific Prostate Society (APPS)
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) 
which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
http://p-international.org/
pISSN: 2287-8882 • eISSN: 2287-903X 
P R O S T A T E  
INTERNATIONAL
Serum level of follicle-stimulating hormone is associated 
with extraprostatic extension of prostate cancer
Hisamitsu Ide, Yuichi Terado1, Kentaro Sakamaki2, Masahiro Inoue, Akiko Nakajima, Yan Lu, Schinichi Hisasue3, 
Raizo Yamaguchi, Satoru Muto, Shigeo Horie3
Department of Urology, Teikyo University School of Medicine, Tokyo, Japan
1Department of Pathology, Kyorin University School of Medicine, Tokyo, Japan
2Department of Biostatistics and Epidemiology, Yokohama City University School of Medicine, Yokohama, Japan
3Department of Urology, Juntendo University Graduate School of Medicine, Tokyo, Japan
Purpose: To determine whether serum follicle-stimulating hormone (FSH) can be used to predict the aggressiveness of prostate 
cancer prior to radical prostatectomy. 
Methods: Ninety-six patients who underwent radical prostatectomy for biopsy proved cT1c-T2N0M0 prostate cancer between 2003 
and 2008 were identified for retrospective analysis. Using univariate regression analysis, potential variables of extraprostatic tumor 
extension were identified, including prostate-specific antigen (PSA), luteinizing hormone, FSH, testosterone, biopsy findings, and age. 
These variables of interest were analyzed by logistic and linear regression analysis to determine if serum FSH is predictive of extraprostatic 
extension. 
Results: Extraprostatic extension was pathologically confirmed in 18 of 96 patients (18.8%). Statistical analysis confirmed that serum 
FSH was significantly associated with extraprostatic extension (P=0.04). However, age, PSA level, Gleason score, number of tumors, 
and serum testosterone level were not found to be independent predictors of extraprostatic extension.  
Conclusions: Selective expression of FSH receptor on the surface of blood vessels of prostate cancers has recently been reported. 
Measuring serum FSH preoperatively in patients with prostate cancer may provide clinically relevant information about extraprostatic 
spread of tumor.
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INTRODUCTION
In patients with prostate cancer, low testosterone level has 
been shown to be associated with advanced tumor stage at 
presentation, positive surgical margins, high Gleason score, 
and worse overall survival [1-5]. We have previously reported 
that low serum testosterone level is a significant predictor of 
high-grade prostate cancer among patients referred for pros-
tate biopsy [6]. Multivariate logistic regression analysis also 
revealed statistically significant differences in serum levels of 
follicle-stimulating hormone (FSH) in patients with and with-
out prostate cancer [6].
 The hypothalamo-pituitary-gonadal axis regulates the pro-
duction of testosterone through luteinizing hormone (LH) 
and FSH secretion. FSH is a key hormone in reproduction. 
It stimulates sertoli cell proliferation in immature testes and 
maintains normal spermatogenesis in adults [7]. FSH binds 
to FSH receptor, which is expressed in both testicular sertoli 
cells and ovarian granulosa cells. FSH receptor is a member 
of the superfamily of receptors, which is characterized by 
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the presence of seven transmembrane structures coupled to 
G-proteins. Although FSH receptor expression has been de-
tected in prostate tissues, including prostate cancer, the direct 
biological function of FSH in prostate carcinogenesis and pros-
tate cancer progression has not been well characterized [8]. 
 Recently, FSH receptor has been detected on the surface 
of blood vessels in a wide range of tumors, including prostate 
[9]. Although signal transduction through G-protein-coupled 
receptors is a major biochemical pathway involved in the 
regulation of cell proliferation by growth factors, the exact 
biological function of FSH signaling in tumor vessels remains 
unknown. FSH receptor expression by endothelial cells may 
be associated with the proliferation and invasiveness of can-
cerous cells. In this study, we investigated the association be-
tween serum FSH levels and extraprostatic extension, based 
on the hypothesis that FSH/FSH receptor signaling may play 
a role in regulating the growth and invasiveness of prostate 
cancers. 
MATERIALS AND METHODS
We reviewed, retrospectively, the medical records of all pros-
tate cancer patients who underwent radical prostatectomy at 
Teikyo University School of Medicine Hospital from January 
2003 through November 2008. Patients eligible for this study 
were unselected and accrued consecutively. This review identi-
fied 96 patients with biopsy and imaging proved cT1c-T2N0M0 
prostate cancer who underwent radical prostatectomy. All 
patients gave written informed consent, and approval was 
obtained from the hospital Research Ethics Board. The histo-
pathological evaluation was performed by a single pathologist 
(Y.T.), and none of the patients had prostate cancer-specific 
treatment before this study. 
 Serum prostate-specific antigen (PSA) levels were measured 
by chemiluminescence enzyme immunoassay with a Lumi-
pulse kit (Fujirebio, Tokyo, Japan). Serum testosterone levels 
were measured using the Architect testosterone kit (Abbott 
Japan, Tokyo, Japan). LH and FSH levels were measured using 
electrochemiluminescence immunoassay with the ECLusys 
kit (Roche Diagnostics, Basel, Switzerland). 
 We performed univariate logistic regression analysis to 
screen for prognostic variables of extraprostatic extension. 
The following potential factors were analyzed: age, tumor size 
(maximal length of tumor of radical prostatectomy specimen), 
number of tumors of radical prostatectomy specimen, serum 
PSA, LH, FSH, and testosterone levels. Using important prog-
nostic factors and variables found to be statistically significant 
on univariate logistic regression analyses, we then performed 
multivariate logistic regression analysis to investigate the 
association between serum level of FSH and extraprostatic 
extension. 
 LH and FSH were evaluated separately to avoid potential 
confounding due to multicollinearity because of the high 
correlation between LH and FSH. We used log-transformed 
values of serum PSA, LH, FSH, testosterone levels, and tumor 
size because of their nonnormal distribution. Similar analy-
ses were performed with linear regression analysis to assess 
the association between serum FSH levels and tumor size. 
Since using either untransformed or log-transformed tumor 
size did not affect the statistical significance on linear regres-
sion analysis, we reported the result of using untransformed 
tumor size, as are more clinically meaningful.
 A P-value of < 0.05 was considered to be statistically signifi-
cant. Analyses were performed using SAS 9.1.3 (SAS Institute 
Inc., Cary, NC, USA).
RESULTS
The characteristics of the study population with radical pros-
tatectomy are shown in Table 1. A single pathologist (Y.T.) 
analyzed the cohorts with respect to pathologic stage, tumor 
numbers and tumor size (maximum length of tumor). Uni-
variate logistic regression analysis revealed statistically signif-
icant differences in PSA (P = 0.01), tumor size (P < 0.001), LH 
(P = 0.004), FSH (P = 0.01), and Gleason score (P = 0.01) in pa-
tients with and without extraprostatic extension (Table 2). On 
the other hand, there were no statistically significant differ-
ences in testosterone levels between these groups (P = 0.22). 
According to the multivariate logistic regression analysis, there 
were statistically significant differences in selected variables, 
such as tumor size (P = 0.04) and FSH (P = 0.04) (Table 3). In 
Table 1. Comparison between the group with and without ex-
traprostatic extension
Variable Total patients
Patients with 
capsule invasion
Patients without 
capsule invasion
No. 96 18 78
Age (yr),  
median (range)
64.3 (43.0–80.0) 65.2 (43.0–75.0) 64.1 (48.0–80.0)
No. of tumors 2.28 1.94 2.36
Tumor size (mm) 9.95 18.88 7.75
PSA 9.83 13.49 8.99
LH 8.22 12.90 7.17
FSH 13.74 23.67 11.57
TST 449.18 412.78 456.71
Gleason score 6.88 7.50 6.73
PSA, prostate-specific antigen; LH, luteinizing hormone; FSH, follicle-
stimulating hormone; TST, testosterone.
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addition, we analyzed each factor associated with tumor size. 
On multivariate linear regression analysis using the variables 
to be statistically significant on the univariate linear regres-
sion analysis, there were statistically significant differences 
in FSH (P= 0.01) and PSA (P< 0.001) for tumor size (Table 4). 
On the basis of these results, we determined that FSH was the 
independent variable with predictive value for extraprostatic 
extension and tumor size.
DISCUSSION
Previous studies have demonstrated the presence of FSH 
receptor expression in tumor cells of prostate cancer by im-
munohistochemical analysis [10,11] and in some cell lines by 
reverse transcription-polymerase chain reaction [12]. Recent-
ly, FSH receptor has also been detected in vessels adjacent to 
the tumor cells of prostate cancer [9]. These results suggest 
that FSH receptor is activated, or signaled, by its ligand FSH, 
and that this signaling may have an important role in pros-
tate carcinogenesis and prostate cancer progression. In the 
present study, we showed that FSH is a significant marker 
of extraprostatic extension in human prostate cancer. The 
finding of increased serum FSH in prostate cancer patients 
who have invasive tumors allows us to hypothesize that FSH 
signaling is involved in prostate cancer progression and in the 
development of extraprostatic spread of tumor. It was previ-
ously shown that binding of FSH and FSH receptor in ovarian 
granulosa cells induces an increase in hypoxia inducible fac-
tor 1 protein levels, which leads to up-regulation of vascular 
endothelial growth factor [13]. This result suggests that FSH 
signaling in prostate cancer cells may promote angiogenesis 
surrounding prostate tumors.
 To determine the precise role of FSH/FSH receptor signal-
ing in prostate cancer, it is necessary to investigate the invasive 
potential of human prostate cancer cell lines that express FSH 
receptor. Our own preliminary data demonstrate that pros-
tate cancer cell lines 22Rv1, LNCaP, and PC-3 express FSH 
receptor (unpublished data). It had been previously reported 
that FSH stimulates the growth of prostate cancer in the PC-3 
cell line [11]. Further study has the potential to elucidate the 
biological role of FSH signaling in prostate cancer cells.
 The next question one has to ask is what is the source of 
elevated serum FSH in patients with prostate cancer? One pos-
sibility for the observed increase in FSH production is stimula-
tion of the anterior pituitary gland through the hypothalamo-
pituitary-gonadal axis. Testosterone reduces FSH production 
by decreasing the hypothalamic secretion of gonadotropin-
releasing hormone, which, in turn, inhibits pituitary produc-
tion of FSH [8]. In other words, when testosterone is decreased 
during the progression of prostate cancer, the negative feed-
back regulatory pathway increases the secretion of FSH in the 
pituitary gland. In this study, however, we did not see any sta-
tistically significant differences in testosterone levels between 
patients with and without extraprostatic extension. The other 
possibility is that the observed increase in FSH is produced by 
the prostatic epithelial cells. In a previous study, the expres-
sion of FSH in human prostate cancer tissues was detected 
by immunohistochemistry, but the cancerous glands stained 
heterogeneously [14]. The most interesting finding was that 
prostate cancer cells in metastatic lymph nodes stained for 
FSH but adjacent normal tissues were negative [14].
Table 2. Logistic regression analysis evaluating risk of extra-
prostatic extension (single regression)
Variable OR (95% CI) P-value
Age 1.03 (0.95–1.14) 0.540
No. of tumors 0.89 (0.66–1.20) 0.450
Gleason score 1.815 (1.14–2.88) 0.010
Log PSA 2.78 (1.23–6.3) 0.010
Log LH 6.41 (1.8–22.9) 0.004
Log FSH 4.04 (1.5–10.84) 0.010
Log TST 0.37 (0.07–1.84) 0.220
Log tumor size 17.85 (3.75–84.85) <0.001
OR, odds ratio; CI, confidence interval; PSA, prostate-specific antigen; 
LH, luteinizing hormone; FSH, follicle-stimulating hormone; TST, testos-
terone.
Table 3. Logistic regression analysis evaluating FSH and risk of 
extraprostatic extension (multiple regression) 
Variable OR (95% CI) P-value
Gleason score 2.04 (0.75–5.54) 0.16
Log PSA 0.65 (0.13–3.29) 0.60
Log tumor size 23.93 (1.10–521.36) 0.04
Log FSH 4.47 (1.09–18.31) 0.04
Luteinizing hormone and FSH were evaluated separately to avoid po-
tential confounding due to multicollinearity.
FSH, follicle-stimulating hormone; OR, odds ratio; CI, confidence inter-
val; PSA, prostate-specific antigen.
Table 4. Linear regression analysis evaluating association of tu-
mor size (multiple regression) 
Variable Parameter (95% CI) P-value
Gleason score 1.51 (0.02–3.00) 0.050
No. of tumors –0.17 (–0.91–0.58) 0.660
Log FSH 2.82 (0.72–4.92) 0.010
Log PSA 5.72 (3.40–8.02) <0.001
Luteinizing hormone and FSH were evaluated separately to avoid po-
tential confounding due to multicollinearity.
CI, confidence interval; FSH, follicle-stimulating hormone; PSA, pros-
tate-specific antigen.
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 In conclusion, in this study, we demonstrate that measur-
ing serum FSH in prostate cancer patients might provide 
clinically relevant information about extraprostatic extension 
of tumor. Finding a more sensitive biomarker for the early 
detection of prostate cancer remains a priority. Information 
about the potential for extraprostatic extension of tumor would 
be particularly useful in weighing the option of radical pros-
tatectomy. The question remains, how precisely does FSH 
contribute to prostate cancer progression? Although further 
study is required, we postulate that blocking FSH and/or FSH 
receptor signaling may be a new strategy in the treatment of 
prostate cancer patients.
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